Table 1.
Several individual markers are differentially methylated between the prognostic groups and neuroblastoma risk factors
| Type | Subtype | KRT19 | FAS | PRPH | CNR1 | QPCT | HIST1H3C | ACSS3 | GRB10 |
|---|---|---|---|---|---|---|---|---|---|
| Prognostic group | LR-SURV | 0/31 (0%) | 1/31 (3%) | 14/31 (45%) | 2/31 (6%) | 18/31 (58%) | 0/31 (0%) | 0/31 (0%) | 6/31 (19%) |
| HR-SURV | 14/30 (48%) | 8/30 (27%) | 24/30 (80%) | 10/30 (33%) | 25/30 (83%) | 2/30 (7%) | 14/30 (47%) | 13/30 (43%) | |
| HR-DOD | 9/28 (32%) | 6/28 (21%) | 19/28 (68%) | 10/28 (36%) | 24/28 (86%) | 6/28 (21%) | 7/28 (25%) | 11/28 (39%) | |
| Stage | Stage 1 | 0/21 (0%) | 0/21 (0%) | 8/21 (38%) | 1/21 (5%) | 13/21 (62%) | 0/21 (0%) | 0/21 (0%) | 4/21 (19%) |
| Stage 2 | 1/12 (8%) | 2/12 (17%) | 8/12 (67%) | 2/12 (17%) | 8/12 (67%) | 0/12 (0%) | 1/12 (8%) | 3/12 (25%) | |
| Stage 3 | 9/17 (53%) | 4/17 (24%) | 13/17 (77%) | 9/17 (53%) | 15/17 (88%) | 3/17 (18%) | 9/17 (58%) | 8/17 (47%) | |
| Stage 4 | 13/39 (33%) | 9/39 (15%) | 28/39 (72%) | 10/39 (26%) | 31/39 (80%) | 5/39 (18%) | 11/39 (28%) | 15/39 (39%) | |
| MYCN | MYCN single copy | 7/50 (14%) | 2/50 (4%) | 24/50 (48%) | 5/50 (10%) | 31/50 (62%) | 0/50 (0%) | 2/50 (4%) | 14/50 (28%) |
| MYCN amplified | 16/39 (41%) | 13/39 (33%) | 33/39 (85%) | 17/39 (44%) | 36/39 (92%) | 8/39 (21%) | 19/39 (49%) | 16/39 (41%) | |
| Age | Age at diagnosis > 12 months | 21/53 (40%) | 14/53 (26%) | 37/53 (69%) | 18/53 (34%) | 46/53 (87%) | 8/53 (15%) | 21/53 (40%) | 24/53 (45%) |
| Age at diagnosis < 12 months | 2/36 (6%) | 1/36 (3%) | 20/396(56%) | 4/36 (11%) | 21/36 (58%) | 0/36 (0%) | 0/36 (0%) | 6/36 (17%) | |
| Age at diagnosis > 18 months | 20/45 (44%) | 13/45 (29%) | 33/45 (73%) | 17/45 (38%) | 40/45 (89%) | 8/45 (18%) | 19/45 (49%) | 23/45 (51%) | |
| Age at diagnosis < 18 months | 3/44 (7%) | 2/44 (5%) | 24/44 (55%) | 5/44 (11%) | 27/44 (61%) | 0/44 (0%) | 2/44 (5%) | 7/44 (16%) | |
| Overall total | 23/89 (26%) | 15/89 (17%) | 57/89 (64%) | 22/89 (25%) | 67/89 (75%) | 8/89 (9%) | 21/89 (24%) | 30/89 (34%) | |
| Statistics (Fisher's exact P-value) | |||||||||
| Prognostic group | <0.001 | 0.151 | 0.112 | 0.068 | 0.165 | 0.0624 | <0.001 | 0.405 | |
| MYCN | 0.0594 | 0.008 | 0.008 | 0.008 | 0.017 | 0.0146 | <0.001 | 0.708 | |
| Stage | 0.007 | 0.287 | 0.221 | 0.059 | 0.683 | 0.448 | 0.008 | 0.700 | |
| Age cutoff 12 months | 0.008 | 0.045 | 0.579 | 0.138 | 0.059 | 0.123 | <0.001 | 0.059 | |
| Age cutoff 18 months | 0.002 | 0.045 | 0.326 | 0.059 | 0.045 | 0.0594 | 0.0015 | 0.012 |
The number (percentage) of methylated samples in each stratum is given. P-values according to the Fisher's exact test, corrected for multiple testing (Benjamini-Hochberg). HR-DOD, high-risk deceased patients; HR-SURV, high-risk patients alive for at least 1,000 days follow-up; LR-SURV, low-risk patients alive for at least 1,000 days follow-up. P-values in bold indicate significant associations.